Navigation Links
Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
Date:8/3/2009

SEATTLE, Aug. 3 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced that clinical data relating to long-term treatment with Stimuvax were presented at the International Association for the Study of Lung Cancer's 13th World Conference on Lung Cancer in San Francisco on August 1, 2009. The presentation by Dr. Glenwood Goss from the Ottawa Hospital Cancer Centre, Ottawa, Ontario, involved 16 patients who received treatment with Stimuvax for between 2 and 8.2 years as part of the Phase 2b trial in patients with stage IIIb/IV non-small cell lung cancer (NSCLC).

As of the time of data analysis in April 2009, 10 of the 16 studied patients were alive without evidence of disease progression, of whom eight continued to receive therapy with Stimuvax after 6.3 to 8.2 years. The remaining two living patients discontinued Stimuvax therapy after 2.4 and 5.8 years, respectively, and were without evidence of disease progression. Nine of the 10 living patients had stage IIIb NSCLC upon entry to the trial, while one had stage IV disease. Six of the 10 living patients had a complete response to their first-line chemotherapy or chemo-radiation, while four patients had stable disease. The remaining six of the 16 patients discontinued Stimuvax after 2.0 to 5.1 years of treatment as a result of disease progression and are deceased.

Prolonged treatment with Stimuvax was well-tolerated in this trial. The most common treatment-related adverse events were injection-site reactions, which tended to diminish after the first year of treatment. There was no evidence of autoimmune reactions with prolonged use.

The Phase 2b trial of Stimuvax in patients with stage IIIb/IV NSCLC was conducted by Oncothyreon, with patient enrollment concluding in 2003. Long-term follow-up of these patients was conducted by Merck KGaA of Darmstadt,
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
2. Oncothyreon appoints Scott Peterson as Vice President of Research and Development
3. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
4. Oncothyreon announces closing of $11.1 million registered direct financing
5. Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing
6. Oncothyreons PX-866 is effective in preclinical model of pulmonary fibrosis
7. Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
8. Oncothyreon reports first quarter 2009 financial results
9. Oncothyreon regains compliance with NASDAQ listing requirements
10. Oncothyreon to present at Invest Northwest 2009
11. Oncothyreon reports full year and fourth quarter 2008 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... ALTO, Calif. , May 17, 2013 /PRNewswire/ ... it has achieved 50% enrollment of the total ... to evaluate the safety and preliminary efficacy of ... Cells) therapy for Knee Osteoarthritis (KOA). To date ... (SAE) reported. The Phase I open ...
(Date:5/17/2013)... , May 17, 2013 /PRNewswire-iReach/ -- Aridis ... been reached with Switzerland -based ... anti-infective human monoclonal antibody (mAb) products, and technologies. ... mAb products for treatment of infections by common ... Staphylococcus aureus , Pseudomonas aeruginosa , ...
(Date:5/17/2013)... May 17, 2013 Men’s skin is biologically ... La-roche Posay ) and has been known to react more ... men may be far from puberty, other acne causing factors ... causing breakouts, and threatening skin with unsightly acne scars. Adult ... Men’s Health on how to reduce and prevent ...
(Date:5/17/2013)... RURO Inc. is pleased to ... versatile refinement to the smart management solution. , ... advanced methodical management for transgenic animal colonies, genotyping ... network-based platform provides user access with a plethora ... to emphasize streamlined tasks, such as animal relocation ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2
... VIENNA, Va., March 10 CEL-SCI Corporation (NYSE Alternext ... to launch a new manufacturing process that could allow ... to maintain their potency and thereby potentially also their ... developed by CEL-SCI may also significantly accelerate the time ...
... Take Market Share Away from Lucentis from 2012 ... Decision ResourcesWALTHAM, Mass., March 10 Decision Resources, ... firms for pharmaceutical and healthcare issues, finds that ... macular degeneration (AMD) market through 2012 will be ...
... Tolerx, Inc., today announced that DEFEND ( D urable ... arly or N ew Onset Type 1 D ... targeted immunotherapeutic, has begun enrollment of new onset autoimmune type ... cell function subsequent to the administration of otelixizumab is the ...
Cached Biology Technology:CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products 2CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products 3CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products 4Robust Annual Growth Through 2012 in the Age-Related Macular Degeneration Market Will Be Driven by Expanding Use of Lucentis in Europe 2Robust Annual Growth Through 2012 in the Age-Related Macular Degeneration Market Will Be Driven by Expanding Use of Lucentis in Europe 3Tolerx Expands Phase 3 'DEFEND' Trial of Otelixizumab in Europe 2Tolerx Expands Phase 3 'DEFEND' Trial of Otelixizumab in Europe 3Tolerx Expands Phase 3 'DEFEND' Trial of Otelixizumab in Europe 4
(Date:5/16/2013)... predict the stability of today,s largest ice sheets in Greenland ... years ago, for example when Earth was going through ... a high sea level due to ice sheet collapse at ... that if the world,s largest ice sheets collapsed in the ... modern, progressively warming world. , However, a new groundbreaking ...
(Date:5/16/2013)... layer lining the body,s blood vessels, is extremely ... thickness, this super-tenuous structure routinely withstands blood flow, ... a unique and highly dynamic barrier that maintains ... body,s circulatory system. , It,s also extremely adaptable. ... breached to enable immune cells to reach ...
(Date:5/16/2013)... , May 16, 2013 Integrated ... combination with a custom thin film transistor camera ... forensic quality roll image in the smallest and ... Sherlock, an Appendix F Mobile ID FAP 45, ... 95% reduction in size and weight when compared ...
Breaking Biology News(10 mins):World's biggest ice sheets likely more stable than previously believed 2Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4
... the first time, scientists have described not only the identities ... in this case, a mouse macrophage or white blood ... and change over time to a bacterial stimulus triggering the ... of the Journal of Biological Chemistry , lead author ...
... of time, the colonial hydrology of the northeastern U.S. has ... social scientists. The results, which extend as far back ... the journal Environmental Science & Technology (ES&T). ... of the past, and will lead to a better understanding ...
... / ST. PAUL (December 1, 2010) University of ... is among an international group of researchers that has ... of sexual maturation in women. Many of these genes ... energy metabolism. Prior to the multi-institutional study, only four ...
Cached Biology News:Researchers describe first functioning 'lipidome' of mouse macrophage 2Researchers describe first functioning 'lipidome' of mouse macrophage 3America's colonial hydrologic history recreated 2U of M researcher helps unlock 30 new genes responsible for early onset puberty 2
quantitation of phosphatase activity, evaluation of hits and leads from HTS...
... ISO 9001:2000 Certified USDA Research Registered ... SOP's Training AALAS Certified Technicians ... Procedures GLP Documentation Upon Request Focus ... point for all your custom immunology service ...
Request Info...
Request Info...
Biology Products: